

Organogel: An Ideal Drug Delivery Carrier for Non Steroidal Anti-Inflammatory Drugs through Topical Route

Balaguru S, Ramya Devi D, Vedha Hari BN*

Department of Pharmaceutical Technology, School of Chemical & Biotechnology, SASTRA University, Thanjavur-613401. India

Available Online: 22nd January, 2015

ABSTRACT

Technological advancement in the field of medicine and pharmaceuticals has made researchers to work in development of novel formulation and advancement in drug delivery systems using well advanced techniques. Among which conventional semi solid topical dosage form of lecithin organogel has got much significance. Lecithin organogel are three dimensional network of jelly like phase with lecithin macromolecule as major gelator compound and proportionate amount of organic and aqueous phase medium in them. They are thermodynamically stable with a nature of biphasic solubility of drugs, good partition coefficient, biocompatible nature with skin and ease of preparation with simple components. Lecithin organogel are mainly used as matrix delivery of various drugs through transdermal route of application. In this current review work, attempts have been made to explain about the types of organogels, gelation mechanism, properties of organogel, parameters influencing in gelation. More over the review mainly focused on categories of drugs loaded in them and their feasibilities in loading NSAID drugs in lecithin organogel.

Keywords: Organogel, NSAIDs, Topical

INTRODUCTION

Over a decade there has been much developments, but still there are many drawbacks in conventional dosage forms like tablets, capsules, parental, rectal, vaginal¹⁻⁴ etc, this lead to the development of novel drug delivery system⁵. Among which novel topical drug delivery systems using lipid based carrier such as Lecithin organogel has attained much importance and demands⁶. Topical drug delivery is the method of delivery of drugs through skin layers for local action and to systemic circulation using different carrier vehicles. Topical dosage forms include creams, pastes, ointments, solutions, gels, and plastizers^{7,8}. They are mainly targeted on pain relief management, anti inflammatory effect, contraceptive devices and in wound healing effects.

Compared to other semi solid topical dosage forms, gels have attained much importance among the other novel topical formulations because of their highlighted properties such as smooth texture, elegant appearance, miscibility with skin layer secretions, transparency, biocompatible, highly penetrable, spreadable, prolonged stability and ease of preparations with simple constituents. Gels constitute a network of structure formed by a solid gelator molecule in addition of solvents to it⁹. Novel semi-solid preparations of gels are mainly categorized in to organogel and hydrogel based on their solvent proportions¹⁰. And they are used in various forms like sustained release, controlled release, extended release, bio adhesive, and in-situ gels etc.

Using these techniques, a wide range of formulations and strategies has been employed for the delivery of various medicaments through skin layers. A recent research on lecithin lipid based molecules has made it as a potential carrier in topical delivery of various medicaments, which mainly includes bioactive agents, antiviral, muscle relaxants and NSAIDs. Recent studies on lecithin phospholipid have enriched lecithin organogel as better lipid based carrier system in novel drug delivery systems.

NSAID
Non Steroidal Anti-Inflammatory Drug (NSAID) is the medicaments mainly targeted in pain management and anti-inflammatory effect. They also possess mild antipyretic and analgesic property^{11,12}. Generally they are available in various formulations like tablets, capsules, liquid orals, gels, eye drops, intravenous injections and suppositories etc., are administered through various routes like oral, ophthalmic, rectal, parental, and mainly through transdermal route. They are also available as over the counter drug and some commercially available drugs for example Aspirin, Ibuprofen, Ketoprofen, Piroxicam, Paracetamol etc. NSAIDs are mainly grouped into two categories, selective and non-selective NSAID. Non selective NSAIDs inhibit both COX-1 and COX-2 enzymes present in all parts of our body causing severe problems and side effects. Some of the commonly available non-selective NSAIDs are Aspirin, Ibuprofen, and Paracetamol etc. Whereas Selective NSAIDs are the COX-2 enzyme inhibitor drugs which are responsible in pain and inflammations. Celecoxib was the first


Figure 1: Schematic diagram of the preparation of lecithin organogels⁵¹

Table 1: Organogel types and model drugs loaded

S. No	Types of Organogel	Ingredients	Model Drugs loaded
1.	Lecithin organogels ¹⁵	Egg Lecithin or soya lecithin, organic solvents, aqueous phase, sorbic acid.	Diclofenac ²⁹ , Indomethacin ³¹ , Piroxicam ³¹ , Aceclofenac ³² , Fluriprofen ³³ , Propranolol ³⁴
2.	Pluronic Lecithin organogels ^{17,18}	Pluronic F127 (poloxamer) polymer. Soya lecithin, sorbic acid, IPM, potassium sorbate, water,	Diclofenac ³⁰ , Ibuprofen ³¹ , Ketoprofen ³⁴
3.	Limonene derived organogels ²⁴	Limonene incorporated within Dibutyl lauroylglutamide (GP1) in propylene glycol	Methimazole ³⁸ Dexamethasone
4.	Non-ionic surfactant based Organogel ²⁵	Cetyl alcohol, Stearyl alcohol, Tween, isopropyl myristate, n-butanol, water	Diclofenac ²⁹ , Ibuprofen ³¹ , Ketoprofen ³³ , Progesterone ³¹
5.	Sorbitan monosterate organogel ²⁶	Span20, Tween80 , isopropyl myristate, non polar solvents like Eucalyptus oil, n-octanol, propylene glycol, PEG (polyethylene glycol), ethyl alcohol, isopropyl alcohol	Cyclosporin A, Zidovudine ³¹ , BSA
6.	Poly ethylene organogels ²⁷	Poly ethylene's, mineral oils, sorbic acid, Aqueous phase.	Antigens, sumatriptan ³⁹ , Clobetasol
7.	Surfactant and polymer based Organogel	Oil phase: Gelucire 44/14, Plurol oleique, Lauroglycol 90 Water phase: Sodium alginate, Glycerin, water	Propionate ³⁹ , Doxorubicin
08	Eudragit Organogel ²⁷	Copolymer of ethyl acrylate, methyl acrylate, polyhydric alcohols, ethylene glycol,	Leuprolide ³¹ , Propranolol hydrochloride ³³ Acyclovir, Salicylic acid ³³

commercially available sulfonamide COX-2 inhibitor in market followed by Rofecoxib, Etoricoxib etc¹³.

Lecithin

Lecithin is a fatty substance with a complex mixture of triglycerides, choline, phosphoric acid, fatty acids and mainly of phosphatidylcholine compounds¹⁴. They are less soluble in water and have good emulsifying property. In aqueous solutions, its lipid compounds form micelles or liposomes which act as surfactant of amphiphilic surfactant possessing both lipophilic and hydrophilic characteristics. Although lecithin is available in natural sources like plant and animal tissues, milk, and marine sources, they are predominantly outsourced from soy bean and egg yolk. Lecithin has a wide range of applications in various fields and recent researches on lecithin phospholipids has got higher priority in pharmaceutical

areas as it can act as an efficient wetting agent, surfactant, solubilizer, emulsifier and penetration enhancers. As a result they are now mainly utilized in preparation of organogel with addition other co-surfactants¹⁵.

Lecithin Organogel

In general, Organogels^{15,16} are semi-solid systems in which a three-dimensional network of gelator molecules are aggregates immobilise an organic liquid continuous phase, typically a non-polar solvent. They consist of an organogelators (lecithin) compounds in them. These compounds form a cross-linked structure either by physical or chemical interactions, thereby immobilising the organic phase within the network. Molecular interactions such as hydrogen bonding and dipolar interactions are responsible for the Organogel structure.

Pluronic lecithin organogel




Figure 2: Categories of Medicaments loaded in Organogel

Pluronic F-127 is a copolymer of polyoxyethylene and polyoxypropylenes, which are also called as poloxamer with a major compound of ethylene oxide makes it hydrophilic¹⁷. They are freely soluble in cold water and at low temperature (4-5°C) they exhibit more as solution form and turns into gel when reaches body temperature. Pluronic polymers are non-toxic, biocompatible and act as a good penetration enhancer without harming the skin layers. These properties confers to the use of Pluronic polymer in preparation of organogel loaded with various medicaments.

Main aspects of preferring Organogel in topical formulation is that drugs of both hydrophilic and lipophilic nature can be loaded in them and they have a good viscoelastic, thermodynamically stable, ease spreadable properties etc. They are mainly used in the targeted drug delivery. Lecithin organogels are attributed because of their importance like bypass first pass metabolism, targeted site of action, gastro intestinal complexity can be avoided, good pharmacological response through skin absorption into systemic circulation, problems of various pH change, gastric enzymes activity, and intravenous therapies etc can be avoided, medication can be stopped when needed, larger surface area of application gives good response, ease of preparation, cost efficient etc.

Properties of lecithin Organogel

Physiochemical properties of lecithin Organogel¹⁸ includes

Viscoelasticity

Lecithin Organogel are three dimensional network structures formed by the physical interaction between the gelator molecules. It consists of surfactant (lecithin) dissolved in a non-polar phase and an aqueous phase. At low shear rate they act as a solid and possess elastic property and increase in shear rate disturbs the interactions between them and makes them to flow this shows the plastic nature of Lecithin organogel¹⁸.

Non-birefringence

Isotropic nature of lecithin Organogel makes them non-birefringence, which do not allow polarized light to pass through their rigid matrices.

Thermal stability

Organogel when heated above its phase transition temperature undergo disruption in physiological interactions between the gelator molecules and flows as liquid phase and again on relaxed cooling, decrease in thermal energy makes them revert and thermally stable^{18,20}.

Optical clarity

Compositions of Organogel determine the transparency nature of the gel, where lecithin added Organogel are transparent and other gelator added gels are opaque in nature.

Biocompatibility

Organogel consists of organic solvents which on continuous administration on skin causes allergic reactions. However recent development in novel topical formulations made use of lecithin and many other mineral oils in Organogel development make them as biocompatible one^{19,21}.

Hydrophilic lipophilic balance

HLB values of lecithin Organogel are well balanced as they contain organic phase and aqueous phase together. Lecithin molecules are amphiphilic in nature and they contain polar head and non polar tail which can attract a wide range of molecules²⁰.

Microbial resistance

Aqueous phase act as a medium for growth of micro organism whereas, Lecithin Organogel consists of an external organic continuum phase which prevents the lecithin and aqueous phase from microbial contamination. Which got entrapped within the three dimensional network of gelation structure formed by the gelator molecule^{15,21}.

Organogelation mechanism

Table 3: Adverse effect of NSAIDs in various organs

S.No	Organ System	Adverse Effects
01	Gastrointestinal ⁴⁴	Dyspepsia, Gastroduodenal ulceration, Bleeding Colitis, Increased UGI ulceration ⁴⁵
02	Hepatic ⁴⁶	Elevated transaminases, Severe hepatic reactions ^{46,47}
03	Cardiovascular ⁴⁸	Arterial thrombosis ⁴⁹
04	Central nervous system ⁴⁹	Dizziness, Somnolence, Cognitive dysfunction, Aseptic meningitis
05	Renal ⁵⁰	Hypertension, Edema, Acute renal failure Interstitial nephritis, Papillary necrosis

Table 2: Categories of drug loaded in organogel

S. No	Category	Medicaments' loaded
01	Antiemetics	Dexamethasone, dimenhydrat, scopolamine
02	Muscle relaxants	Cyclobenzaprine, baclofen, buspirone, nircardipine ⁴²
03	Neuropathy drugs	Clonidine, capsaicin, amitryptiline, gabapentin, phenytoin
04	NSAIDs	Diclofenac ²⁹ , Ibuprofen ³¹ , Aceclofenac ³³ , ketoprofen ³³ , Sumatriptan ³³ , Indomethacin ³³ , Piroxicam ³⁴ , Ketorolac tromethamine ³⁹ , Fluriprofen ³⁵ ,
05	Analgesics	Acetaminophen, hydromorphone, morphine sulphate ³⁷
06	Hormones	Progesterone ³⁷ , testosterone ³⁷
07	Bioactive agents	Vitamin A ³⁷ , vitamin C ³⁴ , Amino acids, Peptides ³⁷
08	Antiviral agent	Acyclovir

Organogel development mainly depends on two factors, first purity of lecithin used and second addition of aqueous phase to it. Mechanism of Organogel formation takes place by two steps, preparation of organic phase and aqueous phase separately. Organic phase is prepared by mixing calculated amount of lecithin in organic solvent and allowed to stand overnight for complete dissolution. And aqueous phase is prepared by adding Pluronic¹⁷ F127 polymer in ice cold water and seen that complete dissolution takes place^{21,22}.

Later addition of aqueous phase to lecithin organic phase under controlled stirring leads to the formation of three dimensional networks of reverse micelles due to the interaction of hydrophilic molecules of lecithin with the polar phase. This confirms the Organogel formation, whereas Excess addition of water leads to deformation of gel.

Parameters influencing organogel formation

Purity

Purity of lecithin used in formulation plays an important role in organogel formation mechanism. Impurities results in deformation of gels²⁰.

Solvent addition

Amount of aqueous phase added to lecithin organic phase determines the organogel formation. Excess addition leads to unstable nature of the organogel and leads to hydrogel formation²².

Surfactants

Different types of surfactants like span, tween, poloxamer, polyethylene, etc. are available with various concentrations and molecular weight, which influences the properties of organogel formed²⁰.

Other parameters like charge, solubility, phase transition temperature, molecular weight etc also influence in organogel formation²³.

Organogel types and drug loaded

Organogels can be prepared by using various gelator molecules and they are grouped bellow with some model drugs loaded in them.

From the above tabulations we could observe that compared to other drugs, NSAID has been incorporated numerous numbers in organogel.

Mechanism of NSAID action

NSAID mainly interact with different types of cyclooxygenases enzymes, which are present in our body performing various actions. Cyclooxygenases (COX-1 enzyme) catalyzes the formation of prostaglandins which are a protective lining layer of stomach preventing from its own acid secretions. Whereas COX-2 enzyme which controls the production of the prostaglandins, a messenger molecule responsible for pain and inflammation. However NSAID act as an anti inflammatory and pain reducing agent by inhibiting the cyclooxygenases enzymes (COX-1 and COX-2 enzyme) present in all parts of our body^{12,13}.

But there are tedious problems in uptake of NSAIDs in excess amount. They cause gastrointestinal ulcers, GIT Irritations, cardiovascular problems etc. Tabulation 3 shows the problems and side effects associated with excess uptake of NSAIDs. So precautions should be followed during administration of these drugs.

To avoid all these problems of NSAID it has been tried in organogel formulations via topical route was successful and benefits of loading in lecithin organogel were given below.

Benefits of NSAID loaded Organogel

- Avoids gastrointestinal irritations, ulcers, bleeding.
- Reduces drug toxicity.
- Can be targeted to specific site of action.
- Both lipophilic and hydrophilic compounds can be incorporated.
- Drug potency can be maintained.
- Ease of preparation with minimal constituents.

Future prospects

Lecithin organogel strongly proves to be a better carrier molecule in topical delivery when compared to other lipid based vesicular systems because of their higher significance values. Apart from phosphatidylcholine, fatty acids and various compounds, lecithin also constitutes many complex molecules and structures which are to be investigated further and their applications in various fields has to be sorted out. Research works on these prospects are focused and attempts were carried out.

CONCLUSION

NSAID being commonly used for anti inflammatory, anti-pyretic, and analgesic property via oral route cause severe problems make the researchers to concentrate on novel delivery system. Which focused in development of NSAID loaded organogels via topical route of administration has gained a better result. Among the other lipid based carrier systems Organogels proves to show an important advantage of increase in shelf life, thermodynamically stable, efficacy and feasibility of the drugs in them. Such novel delivery systems have coined lecithin organogel as a promising effective carrier over other route of delivery of NSAIDs. In future these prospects will lead to the improvisation and development of organogels loaded with other categories of drugs and so on.

ACKNOWLEDGEMENT

Authors are thankful to the management of SASTRA University, Thanjavur for providing the infrastructure and online resources

REFERENCES

1. Srikonda Venkateswara Sastry, Janaki Ram Nyshadham, Recent technological advances in oral drug delivery- a review, *Pharmaceutical Science and Technology Today*.2000;3(4), 113-150.
2. Gulatin N, and Gupta H, Parenteral drug delivery- a review, *Journal of Drug Delivery and Formulations*.2011;5(2), 133-45.
3. Kanamoto I, Nakagawa T, Horikoshi I, Koizumi T, Pharmacokinetics of two rectal dosage forms of ketoprofen in patients after anal surgery, *Journal of Pharmacodynamics*.1988; 11(3), 141-145.
4. Ceschel GC, Maffei P, Lombardi Borgia S, Rossi S, Development of a mucoadhesive dosage form for vaginal administration. *Journal of Drug Development and Industrial Pharmacy*.2001;27(6), 541-547.
5. Parthasarathi, Bhattacharjee, Sandeep Kumar, An overview of Novel Drug Delivery Systems (NDDS). ISSN: 0974-6943.
6. Costas Kaparissides, Sofia Alexandridou, Katerina Kotti and Sotira Chaitidou, Recent Advances in Novel Drug Delivery Systems. *Azozono-Journal of nanotechnology online*.
7. <http://www.pharmainfo.net/free-books/topical-formulations>.
8. Prausnitz, M.R, Mitragotri.S, Langer.R, Current status and future potential of transdermal drug delivery, *Journal of Drug Delivery and Formulations*. 2004;3, 115-124.
9. Almdal.K, Towards a phenomenological definition of the term 'gel' *Journal of Pharmaceutics*.1993,1, 5-17.
10. Shapiro, Y.E. Structure and dynamics of hydrogels and organogels: An NMR spectroscopy approach. *Journal of polymer science*.2010,2(2).
11. www.google.com/en.Wikipedia.org/lecithin.
12. [www.google.com/en.Wikipedia.org/non-steroidal anti-inflammatory drug](http://www.google.com/en.Wikipedia.org/non-steroidal-anti-inflammatory-drug).
13. Geba GP, Weaver AL, Polis AB, Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. *JAMA* 2002, 27;287(8), 989.
14. Sarath.G, Chandra Reddy, Organogels- A Review, *International Journal Of Pharmacy & Technology*.2010, 2(4), 584- 602.
15. Scartazzini, R. and P.L. Luisi, Organogels from lecithin. *Journal of Physical Chemistry*. 1988,9(2), 829-833.
16. Sahoo.S, Kumar.N, Bhattacharya.C, Sagiri.S.S, Jain.K, Pal.K, Ray.S.S Nayak.B, Organogels: Properties and Applications in drug delivery, Designed monomers and polymers.2011,1(4), 95-108.
17. Varsha Agrawal, Vandana Gupta, Suman Ramteke, Piyush Trivedi, Preparation and Evaluation of Tubular Micelles of Pluronic Lecithin Organogel, *AAPS Pharm SciTech*. 2010,11(4), 1718-1725.
18. Shchipunov, Y.A., Lecithin organogels: rheological properties of polymer-like micelles formed in the presence of water, *Journal of Colloidal System*.1995, 5(7), 556-560.
19. Murdan.S, A review of pluronic lecithin organogel as a topical and transdermal drug delivery system. *Hospital Pharmacist*, 2005, 12, 267-270.
20. Rajiv Kumar, Om Prakash Katore. Lecithin Organogels as a Potential Phospholipid-Structured System for Topical Drug Delivery: A Review. *AAPS PharmSciTech* 2005, 6 (2).
21. Willmann.H, Walde.R, Luisi P.L, Lecithin organogels as matrix for transdermal transport of drugs. *Journal of Pharmaceutical Science*.1991, 81, 871-874.099
22. Schurtenberger p, Scartazzini R, Structural and dynamic properties of polymer like reverse micelles, *Jou Phys Chem*. 1990,94,3695-3701.
23. Suzuki M. L-lysine based Gemini organogelators: their Organogelation properties and thermal stability of organogels. *Jou of org Biomol Chem*, 2003,1(22), 4124-4131.
24. Lim, P.F.C, Limonene GP1/PG organogel as a vehicle in transdermal delivery of haloperidol. *International Journal of Pharmaceutics*. 2006, 311(1-2), 157-164.
25. Murdan, S, Gregoriadis.G, Florence A.T, Non-ionic surfactant based organogels incorporating niosomes. *Journal of Pharma Sciences*. 1996, 6(1), 44-48.
26. Murdan.S, G. Gregoriadis, and A.T. Florence, Novel sorbitan monostearate organogels, *Journal of Pharmaceutical Sciences*. 1999, 88(6), 608-614.
27. Yu. L. Khromova.E, Shumilina. V, Yu. A. Shchipunov, Lecithin organogels containing poly (ethylene glycol) monolaurate, *Journal of Colloidal System*.2001, 63(2), 242-247.

28. Duchateau, S.M.J.E, Organogel-Based Emulsion Systems, Micro-Structural Features and Impact on In Vitro Digestion, *Journal of American Oil Chemistry Society*.2009, 86,733-41.
29. Anda Vintiloiu, Jean-Christophe Leroux, Organogels and its use in drug delivery, *Journal of Controlled Release*.2008,12(8), 179–192.
30. Bindu Nair, Regina Taylor-Gjevre, A Review of Topical Diclofenac Use in Musculoskeletal Disease, *Journal of Pharmaceutics*. 2010, 3, 1892-1908.
31. Swapnil P. Thorat, Smita I. Rane, Formulation and in vitro evaluation of lecithin (soya and egg) based aceclofenac organogels, *Journal of Pharmacy Research*. 2010, 3(6), 1438-1441.
32. Lakshmi P.K, Marka Kranthi kumar, Aishwarya Sridharan, Shyamala Bhaskaran, Formulation and evaluation of ibuprofen topical gel: a novel approach for penetration enhancement, *International Journal of Applied Pharmaceutics*. 2011,3(3).
33. Shaikh M, Jadhav SL, Kadam VJ and Pisal SS, Aceclofenac Organogels; In-vitro and InVivo Characterization, *Journal of Current Drug Delivery Systems*. 2009, 6, 1- 7.
34. Sudaxshina Murdan, A review of Pluronic lecithin organogel as transdermal dermal delivery of drugs. *Hospital pharmacist*. 2005,12, 265-271.
35. Hadidi.N, Nazari N, Aboofazeli R. Formulation and optimization of microemulsion-based organogels containing propranolol hydrochloride using experimental design methods, *DARU*.2009,17(3), 217-225.
36. Kesavan Bhaskar, Jayaraman Anbu, Velayutham Ravichandiran, Vobalaboina Venkateswarlu Yamsani Madhusudan Rao, Lipid nanoparticles for transdermal delivery of flurbiprofen formulation, in vitro, ex vivo and in vivo studies, *Lipids in Health and Disease* 2009, 8(6).
37. Sushil Raut, Santosh Singh Bhadoriya, Lecithin organogel: A unique micellar system for the delivery of bioactive agents in the treatment of skin aging, *Journal of Acta Pharmaceutica Sinica*.2012, 2(1), 8-15.
38. Paice, J.A, Morphine Bioavailability from a Topical Gel Formulation in Volunteers. *Journal of Pain and Symptom Management*. 2008, 35(3), 314-320.
39. Angela Attar Nasserri, Reza Aboofazeli, Hossein Zia, Thomas E Needham, Lecithin – Stabilized Microemulsion – Based Organogels for Topical Application of Ketorolac Tromethamine. In vitro Release Study. *IJPR*, 2003, 2, 117.
40. Mandal Surjyanarayan, Mandal Snigdha. S, Sawant Krutika K, Lecithin Stabilized Organogel: Design and Development for Topical Application of Clobetasol Propionate, *International journal of Pharmaceutical Technology*.2010, 2(2), 1133-1138.
41. Hadgraft.J, Plessis.J, Goosen.C, The selection of nonsteroidal anti-inflammatory agents for dermal delivery. *International Journal of pharmacy*.2000, 207, 31–37.
42. Suhang.H, Jungchu.W, Physicochemical and release studies of naproxen in poloxamer gel. *International Journal of pharmacy*.19, 96, 12913-20.
43. Aboofazeli RZ, Zia H, Needham TE. Transdermal delivery of nicardipine: an approach to in vitro permeation enhancement, *Journal of Drug Delivery*. 2002, 9, 239-247.
44. Silverstein FE, Faich G, Goldstein JL. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. *Celecoxib Long-term Arthritis Safety Study*. *JAMA*. 2000, 284(10),1247-55.
45. Simon LS, Weaver AL, Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. *JAMA*. 1999, 282(20), 1921-8.
46. Ihab Hajj, Shahid M Malik, Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation. *World J Gastroenterol* 2009, 15(31), 3937-3939.
47. James H, Tabibian, Neshan Tabibian, Late-onset celecoxib-induced combined hepato-nephrotoxicity. *Br J Clin Pharmacol*. 2008; 66(1), 150–151.
48. Ragia Hegazy, Mohamed Alashhab, Cardiorenal Effects of Newer NSAIDs (Celecoxib) versus Classic NSAIDs (Ibuprofen) in Patients with Arthritis. *Journal of Toxicology*. 2011, 300-8.
49. Solomon SD, McMurray JJ, Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. *N Engl J Med*. 2005, 352(11), 1071-80.
50. Mike Stubanus a, Günter AJ Riegger a Renal side-effects of cyclo-oxygenase-type-2 inhibitor use. *The Lancet*, 2005, 355, Issue 9205,753.
51. Accessed online <http://www.plo-gel.com/Main/plo-gel.php>
52. Pawar Vinita, Mishra Kumar Shiv, Yadav Mahavir, Tiwari Archana, Liposome: A powerful Approach Estimates Drug Delivery System, *Int J Drug Delivery Tech*. 3(2), 4-7